Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>G Sachs: CN Healthcare Sector to Be More Normalized This Yr w/ No V-shape Recovery in Sight
Recommend 33 Positive 47 Negative 18 |
||||
|
||||
|
2025 will be a more normalized year for China's healthcare industry, with pharma firms expected to gradually adapt to the new norm, Goldman Sachs released a research report saying. However, the industry is not yet expected to quickly recover from the impact of policies like recent anti-corruption, national healthcare insurance disease diagnosis related group (DRG) reform and achieve a V-shape recovery. In addition, Goldman Sachs believed that the application of AI is too early to have a significant impact on the industry in the short term, although generative AI has become a buzzword in the pharma industry. Goldman Sachs lowered its target price for covered Chinese healthcare companies by -8% to +13%, based on recent industry development trends, including more policy support for innovative drugs, the impact of volume-based procurement on biosimilars and the demand and price trend of APIs, etc.. Currently, Goldman Sachs rated HANSOH PHARMA (03692.HK), SINO BIOPHARM (01177.HK) and CSPC PHARMA (01093.HK) at Buy, with ratings at Neutral on FOSUN PHARMA (02196.HK), LIVZON PHARMA (01513.HK), 3SBIO (01530.HK), UNITED LAB (03933.HK), SINOPHARM (01099.HK) and CHINARES PHARMA (03320.HK). The broker also rated HEPALINK (09989.HK) and SH PHARMA (02607.HK) at Sell. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
